A new validated clinical tool that integrates clinicopathologic and genomic features can guide adjuvant chemotherapy of hormone receptor–positive, HER2-negative, axillary node-negative breast cancer with greater precision than either clinicopathologic or genomic data alone, according to data presented at the 2020 annual meeting of the San Antonio Breast Cancer Symposium.
The tool, called RSClin (Genomic Health), provides individualized estimates of distant recurrence risk and absolute